|
1）Key NS. Epidemiologic and clinical data linking factors XI and XII to thrombosis. Hematology Am Soc Hematol Educ Program. 2014; 2014: 66-70
|
|
|
|
2）Mandle RJ, Kaplan AP. Hageman-factor-dependent fibrinolysis: generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen. Blood. 1979; 54: 850-62
|
|
|
|
|
|
3）van Montfoort ML, Meijers JC. Recent insights into the role of the contact pathway in thrombo-inflammatory disorders. Hematology Am Soc Hematol Educ Program. 2014; 2014: 60-5
|
|
|
|
|
|
4）Salomon O, Steinberg DM, Zucker M, et al. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2011; 105: 269-73
|
|
|
|
|
|
5）Boehlen F, Casini A, Pugin F, et al. Pulmonary embolism and fatal stroke in a patient with severe factor XI deficiency after bariatric surgery. Blood Coagul Fibrinolysis. 2013; 24: 347-50
|
|
|
|
|
|
6）Ratnoff OD, Busse RJ, Sheon RP. The Demise of John Hageman. N Engl J Med. 1968; 279: 760-1
|
|
|
|
|
|
7）Girolami A, Candeo N, De Marinis GB, et al. Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation. J Thromb Thrombolysis. 2011; 31: 57-63
|
|
|
|
|
|
8）Zeerleder S, Schloesser M, Redondo M, et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency--a study on 73 subjects from 14 Swiss families. Thromb Haemost. 1999; 82: 1240-6
|
|
|
|
|
|
9）Jones DW, Gallimore MJ, MacKie IJ, et al. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol. 2000; 110: 721-6
|
|
|
|
|
|
10）Löwenberg EC, Meijers JC, Monia BP, et al. Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost. 2010; 8: 2349-57
|
|
|
|
|
|
11）Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015; 372: 232-40
|
|
|
|
|
|
12）Younis HS, Crosby J, Huh JI, et al. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood. 2012; 119: 2401-8
|
|
|
|
|
|
13）McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem. 1999; 274: 1715-22
|
|
|
|
|
|
14）Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010; 116: 4684-92
|
|
|
|
|
|
15）Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014; 123: 2102-7
|
|
|
|
|
|
16）Larsson M, Rayzman V, Nolte MW, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. 2014; 6: 222ra17
|
|
|
|
|
|
17）Robert S, Bertolla C, Masereel B, et al. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008; 51: 3077-80
|
|
|
|
|
|
18）Kraft P, Schwarz T, Pochet L, et al. COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke. Exp Transl Stroke Med. 2010; 2: 5
|
|
|
|
|
|
19）Puy C, Tucker EI, Matafonov A, et al. Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. Blood. 2015; 125: 1488-96
|
|
|
|
|